Research Article
Risk of Gastrointestinal Bleeding with Rivaroxaban: A Comparative Study with Warfarin
Table 1
Demographic and clinical characteristics of patients in both groups.
| | Patients’ characteristics | Rivaroxaban | Warfarin | value | | () | () |
| | Mean age ± SD | 68.25 ± 14.97 | 71.35 ± 13.09 | 0.0573 |
| | Age ≥ 65 | 85 (57.82%) | 104 (67.97%) | 0.0738 | | Age < 65 | 62 (42.18%) | 49 (32.03) |
| | Gender | | | | | Female | 77 (52.38%) | 83 (54.25%) | 0.8170 | | Male | 70 (47.62%) | 70 (45.75%) |
| | Ethnic group | | | | | White | 113 (76.87%) | 133 (86.93%) | | | AA | 14 (9.52%) | 4 (2.61%) | | Others | 20 (13.61) | 16 (10.46%) |
| | Indication for drug | | | | | AF | 69 (46.94%) | 93 (60.78%) | < | | VTE treatment | 12 (8.16%) | 56 (36.60%) | | VTE prophylaxis | 60 (40.82%) | 2 (1.31%) | | Other | 6 (4.08%) | 2 (1.31%) |
| | Low dose | 60 (40.82%) | NA | |
| | High dose | 87 (59.18%) | NA | |
| | Mean duration being on drug (Days) ± SD | 92.19 ± 119.91 | 252.95 ± 167.91 | < |
| | Duration ≤40 days | 81 (55.10%) | 16 (10.46%) | < |
| | Concomitant with aspirin | 56 (38.10%) | 63 (41.18%) | 0.6372 |
| | Concomitant with thienopyridine | 12 (8.16%) | 27 (17.65%) | 0.0163 |
| | Dual antiplatelet agents | 8 (5.44%) | 15 (9.80%) | 0.1558 |
| | Concomitant with NSAIDs | 14 (9.52%) | 7 (4.58%) | 0.1144 |
| | Hb < 12 | 55 (39.29%) | 54 (35.29%) | 0.5454 | | Missing data | 7 | 0 |
| | Cr > 1.5 | 6 (4.23%) | 15 (9.80%) | 0.0714 | | Missing data | 5 | 0 |
| | GFR ≤ 30 | 2 (1.41%) | 6 (3.92%) | 0.2851 | | Missing data | 5 | 0 |
| | ALT > 40 | 11 (9.91%) | 28 (20%) | | | Missing data | 36 | 13 |
| | BMI | | | | | <18.5 | 5 (3.52%) | 0 (0%) | 0.0707 | | 18.5–24.9 | 31 (21.83%) | 35 (22.88%) | | >25 | 106 (74.65%) | 118 (77.12%) | | Missing data | 5 | 0 |
| | Previous GI bleeding | 5 (3.40%) | 15 (9.80%) | |
|
|
AA: African American, AF: atrial fibrillation, ALT: alanine aminotransferase, BMI: body mass index, Cr: creatinine, GFR: glomerular filtration rate, GI: gastrointestinal, Hb: hemoglobin, NSIADs: nonsteroidal anti-inflammatory drugs, and VTE: venous thromboembolism events. Signifying statistical significant values.
|
